Research
Optimized psilocybin production in tryptophan catabolism‐repressed fungi
Microbial Biotechnology – November 01, 2024
Summary
A significant breakthrough in Biology and Chemistry has dramatically boosted psilocybin production, crucial for Psychedelics and Drug Studies. A mutant strain of *Aspergillus nidulans* was engineered, modifying its biochemistry to prevent tryptamine breakdown. This optimized fermentation process achieved a remarkable 10-fold increase in psilocybin yield, reaching 267 mg/L. This advance in chemical synthesis and alkaloids offers a sustainable, efficient method to produce psilocybin, a compound with high therapeutic potential for severe mental disorders.
Abstract
Abstract The high therapeutic potential of psilocybin, a prodrug of the psychotropic psilocin, holds great promise for the treatment of mental diso...
Phytochemical screening, phenolic and flavonoid contents, psilocybin, antioxidant, and acetylcholinesterase inhibition activities of the aqueous extract from the fungi Cyathus striatus, Laternea dringii, and Marasmius haematocephalus
Brazilian Journal of Science – November 01, 2024
Summary
Certain mushrooms exhibit remarkable potential for neuroprotection. Extracts from *Marasmius haematocephalus* showed strong acetylcholinesterase inhibition at 77.14%, with *Laternea dringii* at 68.53%, suggesting applications for Neurodegenerative Diseases. These fungi, significant in Fungal Biology and Applications, contain diverse phytochemicals, including flavonoids (up to 56.06 mg QE g TFC-1). Their natural chemistry offers antioxidant benefits. While chemical synthesis and alkaloids are explored, the investigation also considered psilocybin, aligning with traditional medicine's interest in fungal compounds.
Abstract
Various families of mushrooms contain important phytochemicals with significant potential. This study aimed to investigate the phytochemical prospe...
Ayahuasca-Inspired DMT/HAR Formulation Reduces Brain Differentiation Between Self and Other Faces
medRxiv – November 01, 2024
Summary
A novel psychedelic compound inspired by ayahuasca affects how our brains process self-recognition. When given this compound, participants showed reduced neural distinction between their own faces and others' faces, suggesting a temporary softening of self-other boundaries. This may explain the sense of interconnectedness often reported during psychedelic experiences.
Abstract
Ayahuasca-Inspired DMT/HAR Formulation Reduces Brain Differentiation Between Self and Other Faces
Effect of Ketamine on the Bispectral Index, Spectral Edge Frequency, and Surgical Pleth Index During Propofol-Remifentanil Anesthesia: An Observational Prospective Trial.
Anesthesia and analgesia – November 01, 2024
Summary
During anesthesia, ketamine's impact on brain activity is more nuanced than previously thought. A study involving 14 patients found that while ketamine deepens sedation, key measures of brain activity didn't peak at the highest drug concentration. Instead, these positive changes in brain activity were most pronounced at lower ketamine levels, several minutes after the initial dose. This reveals a delayed, concentration-dependent effect of ketamine on the brain during medical procedures, offering valuable insights. Pain response indicators, however, remained unaffected.
Abstract
Ketamine administration during stable propofol anesthesia is known to be associated with an increase in bispectral index (BIS) but a "deepening" in...
Disrupted Human-Dog Interbrain Neural Coupling in Autism-Associated Shank3 Mutant Dogs.
Advanced science (Weinheim, Baden-Wurttemberg, Germany) – November 01, 2024
Summary
Dogs and humans can synchronize their brain activity during bonding moments like petting and eye contact. Scientists found that this neural connection grows stronger as relationships deepen. In dogs with Shank3 mutations linked to autism spectrum disorders, this brain synchronization is disrupted. Remarkably, treatment with LSD restored normal brain coupling and social attention in affected dogs.
Abstract
Dogs interact with humans effectively and intimately. However, the neural underpinnings for such interspecies social communication are not understo...
How Psychedelics Modulate Multiple Memory Mechanisms in Posttraumatic Stress Disorder.
Drugs – November 01, 2024
Summary
No Summary
Abstract
Posttraumatic stress disorder (PTSD) is a psychiatric disorder with defining abnormalities in memory, and psychedelics may be promising candidates ...
Classical psychedelics' action on brain monoaminergic systems.
The international journal of biochemistry & cell biology – November 01, 2024
Summary
No Summary
Abstract
The study of the mechanism of action of classical psychedelics has gained significant interest due to their clinical potential in the treatment of ...
Preliminary Evidence of Sleep Improvements Following Psilocybin Administration, and their Involvement in Antidepressant Therapeutic Action
Current Psychiatry Reports – November 01, 2024
Summary
Severe insomnia and sleep disturbances can hinder psilocybin's antidepressant effects in treating major depressive disorder. While clinical trials demonstrate large improvements in depressive symptoms, psilocybin's direct impact on sleep quality has been less explored in psychology and psychiatry. Preliminary clinical psychology data suggests both depression and sleep issues decrease after psilocybin use, though sleep improvements are smaller. This highlights a critical intersection for mental health research topics and medicine. Addressing sleep, perhaps related to tryptophan pathways, could optimize psychedelic-assisted therapy, leading to more effective strategies in drug studies and clinical trials for depression.
Abstract
Abstract Purpose of the study Psilocybin is a rapidly-emerging treatment for depression, yet its impact on sleep is not well understood. We sought ...
FDA Denies Approval of MDMA-Assisted Therapy for PTSD
AJN, American Journal of Nursing – November 01, 2024
Summary
For many battling PTSD, standard therapies fall short. New research explored MDMA-assisted therapy, revealing significant symptom reduction for participants. Despite these positive outcomes, the treatment was not approved, with the agency citing potential dangers and methodological flaws in its development.
Abstract
The agency cited potential dangers and flaws in research methodology.
Retraction Note: Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Psychopharmacology (Berl) – November 01, 2024
Summary
Remarkably, individuals undergoing MDMA-assisted psychotherapy for PTSD experienced sustained symptom relief. Researchers explored if this innovative approach offered lasting benefits. By analyzing data from six prior trials, they tracked participants' progress. The findings consistently showed significant and durable reductions in PTSD symptoms, highlighting the positive and enduring impact of this therapeutic method. This offers compelling evidence for long-term recovery.
Abstract
Retraction Note: Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 t...
Therapeutic potential of ketamine in management of epilepsy: Clinical implications and mechanistic insights.
Asian journal of psychiatry – November 01, 2024
Summary
Ketamine, traditionally used for anesthesia, shows promising results in controlling seizures when conventional treatments fail. The drug works by restoring balance between excitatory and inhibitory brain signals, making it particularly valuable for drug-resistant epilepsy. Studies reveal it can reduce seizure frequency and protect brain cells, offering hope for the 30% of epilepsy patients who don't respond to standard medications.
Abstract
Epilepsy, a widespread neurological disorder, affects approximately 50 million people worldwide. This disorder is typified by recurring seizures du...
Misrepresentation of MDMA in the United States, 1999-2023.
Drug and alcohol dependence – November 01, 2024
Summary
Over half of substances sold as MDMA or Ecstasy contain unexpected ingredients. Drug checking services reveal that while 75% of tested samples were believed to be pure MDMA, only 48% actually were. Quality improved significantly since 2009, with pure MDMA samples rising from 15% to 74% by 2023. Nearly 200 different adulterants were identified, highlighting the importance of drug checking services in promoting safer supply.
Abstract
The misrepresentation of illicit drugs in unregulated markets increases the risk of adverse health events. This study analyzed drug checking data t...
Rethinking the role of TRKB in the action of antidepressants and psychedelics.
Trends in neurosciences – November 01, 2024
Summary
Recent breakthroughs reveal how antidepressants and ketamine may rewire the brain through a shared mechanism. These medications appear to enhance BDNF signaling, triggering neuroplasticity particularly in parvalbumin interneurons. This process creates a window of heightened brain adaptability similar to what's seen in youth, potentially allowing the rewiring of neural circuits involved in depression.
Abstract
Antidepressant drugs promote neuronal plasticity, and activation of brain-derived neurotrophic factor (BDNF) signaling through its receptor neurona...
Psychoactive substances for the treatment of neuropsychiatric disorders.
Asian journal of psychiatry – November 01, 2024
Summary
Groundbreaking treatments using psychedelics are transforming mental healthcare. Ketamine offers rapid relief for severe depression, while MDMA shows remarkable success in treating PTSD. These substances, along with other psychedelics, work by altering brain chemistry and enhancing emotional processing. Clinical trials reveal significant improvements in patients with various neuropsychiatric disorders, often after just a few supervised sessions.
Abstract
In the contemporary landscape of psychiatric medicine, critical advancements have been noted in the utilization of psychoactive substances such as ...
Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – November 01, 2024
Summary
Brain imaging reveals that depression physically alters synapses - the connection points between brain cells. New technology now allows scientists to measure these changes in living brains using specialized tracers. Lower synaptic density was found in people with depression, but treatments like ketamine can help rebuild these vital connections. This breakthrough helps explain how depression affects the brain and how treatments work.
Abstract
The development of novel radiotracers for Positron Emission Tomography (PET) imaging agents targeting the synaptic vesicle glycoprotein 2 A (SV2A),...
The effect of a subclinical dose of esketamine on depression and pain after cesarean section: A prospective, randomized, double-blinded controlled trial.
Medicine – November 01, 2024
Summary
A single low dose of esketamine after C-section delivery showed promise in reducing post-surgical pain, though it didn't affect postpartum depression rates. In this 150-patient trial, mothers who received esketamine reported significantly less pain for the first 24 hours after surgery compared to those given a placebo. While some temporary side effects occurred, they resolved quickly, suggesting this could be a valuable option for managing post-cesarean discomfort.
Abstract
The aim of this randomized, double-blind placebo-controlled clinical trial was to study the effects of subclinical doses of esketamine on postpartu...
Psychedelic mushroom-containing chocolate exposures: Case series.
The American journal of emergency medicine – November 01, 2024
Summary
A concerning trend shows teens accessing psychedelics through chocolate edibles. Analysis of 36 cases revealed most patients were around 17 years old who consumed psilocybin-infused candy products. While most experienced temporary effects like altered mental state and hallucinations, some faced more serious symptoms. Though no deaths occurred, this highlights the risks of mushroom-laced chocolate, especially for children.
Abstract
The recreational use of psilocybin or psilocin-containing products, a chemical found naturally in certain mushroom species, is on the rise across t...
Psilocybin administered following extinction sessions does not affect subsequent cocaine cue reinstatement in male and female rats and mice.
Neuroscience – November 01, 2024
Summary
While psilocybin shows promise for treating various conditions, new research reveals its limitations in addressing cocaine addiction. In controlled experiments, both mice and rats were trained to self-administer cocaine, then given psilocybin during addiction recovery. Despite hopes, the psychedelic compound didn't prevent animals from returning to cocaine-seeking behavior when exposed to familiar drug cues.
Abstract
There are currently no pharmacological treatments for cocaine use disorder. Recently there has been a great deal of interest in the potential of ps...
Psychoanalysis and psychedelics: The censored story in Argentina.
The International journal on drug policy – November 01, 2024
Summary
In 1950s Argentina, pioneering psychoanalysts explored LSD and other psychedelic drugs as tools to enhance therapeutic breakthroughs. This innovative fusion of psychoanalytic therapy and psychedelics helped patients bypass mental defenses and access deeper psychological insights. Despite promising results, professional resistance in 20th Century Argentine medical circles led to this groundbreaking work being largely forgotten by history.
Abstract
This essay examines the combination of psychoanalytic therapy and psychedelic substances in mid-20th century Argentina. Through document analysis, ...
Modulation of Posterior Default Mode Network Activity During Interoceptive Attention and Relation to Mindfulness.
Biological psychiatry global open science – November 01, 2024
Summary
No Summary
Abstract
Interoceptive attention to internal sensory signals, such as the breath, is fundamental to mindfulness. However, interoceptive attention can be dif...
Worsening suicidal ideation and prolonged adverse event following psilocybin administration in a clinical setting: case report and thematic analysis of one participant's experience
BJPsych Open – November 01, 2024
Summary
Psilocybin, a promising hallucinogen in medicine, can paradoxically trigger severe adverse effects while fostering personal growth. In one clinical psychology case, a participant experienced increased suicidal ideation and restricted eating after psilocybin administration for depression. Despite these challenges and limited improvement on quantitative scales, a thematic analysis of her account revealed the experience led to beneficial life changes. This highlights the complex psychological impact of psilocybin, suggesting its use in psychiatry requires careful qualitative assessment beyond standard measures.
Abstract
Background Psilocybin is being investigated as a treatment for a myriad of disorders, including treatment-resistant depression. The main focus has ...
Serotonin Transporter (SLC6A4) and FK506-Binding Protein 5 (FKBP5) Genotype and Methylation Relationships with Response to Meditation in Veterans with PTSD.
Molecular neurobiology – November 01, 2024
Summary
No Summary
Abstract
Meditation-based interventions are novel and effective non-pharmacologic treatments for veterans with PTSD. We examined relationships between treat...
Residential Meditation Retreats: A Promise of Sustainable Well-Being?
Cureus – November 01, 2024
Summary
No Summary
Abstract
Meditation retreats are structured programs that immerse participants in focused meditation, mindfulness, and self-reflection over extended periods...
Efficacy of Low-Dose Ketamine and Propofol in the Treatment of Experimental Refractory Status Epilepticus on Male Rats.
Journal of neuroscience research – November 01, 2024
Summary
A breakthrough in epilepsy treatment shows that combining low doses of ketamine and propofol can effectively control severe seizures. In tests with rats experiencing drug-resistant status epilepticus (triggered by lithium-pilocarpine), the combination therapy worked as well as higher doses of single medications, but with fewer side effects. This approach could offer safer treatment options for difficult-to-treat seizures.
Abstract
Refractory status epilepticus (RSE) is a condition with serious mortality and morbidity rate, resistant to benzodiazepine and second-line antiepile...
Ketamine plus midazolam compared to midazolam infusion for the management of refractory status epilepticus.
Clinical neurology and neurosurgery – November 01, 2024
Summary
Stopping severe, prolonged seizures faster is crucial in neurocritical care. A key question was whether adding ketamine to midazolam could end refractory status epilepticus (RSE) sooner than midazolam alone. Analyzing patient data, it was found that while initial midazolam response was similar, introducing ketamine significantly reduced the time to stop Status Epilepticus, including cases of Super refractory status epilepticus. This suggests a beneficial role for ketamine in accelerating seizure control.
Abstract
Data for the use of ketamine (Ket) in treatment of refractory and super-refractory status epilepticus (RSE, SRSE) is lacking despite its widespread...
Post mortem chiral analysis of MDMA and MDA in human blood and hair.
Forensic science international – November 01, 2024
Summary
Despite widespread Ecstasy use, fatal overdoses are relatively rare. Forensic toxicology experts examined post mortem blood and hair samples from MDMA-related deaths using advanced chiral analysis. The research revealed that higher levels of specific MDMA variants correlate with longer survival times after overdose, challenging assumptions about how the drug's metabolism affects fatal outcomes.
Abstract
Drug-related fatalities in the EU are predominantly associated with opioids. MDMA (Ecstasy) consumption results in fewer lethal intoxications despi...
Improved implicit self-esteem is associated with extended antidepressant effects following a novel synergistic intervention.
Molecular psychiatry – November 01, 2024
Summary
A groundbreaking depression treatment combining ketamine with digital self-association training shows promise in rewiring negative self-perception. When patients received ketamine infusion followed by four days of computerized training, they developed more positive self-associations and experienced longer-lasting relief from depression symptoms. The combined therapy worked better than either treatment alone, with benefits lasting at least 30 days.
Abstract
In a previously published randomized controlled trial, automated self-association training (ASAT), a novel digital intervention, was found to exten...
Ketamine reduces seizure and interictal continuum activity in refractory status epilepticus: a multicenter in-person and teleneurocritical care study.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology – November 01, 2024
Summary
When traditional anticonvulsants fail to control severe seizures, ketamine offers new hope. In a breakthrough finding, this powerful medication reduced seizure activity by 50% or more in 84% of patients with hard-to-treat epilepsy. Doctors monitored brain activity through electroencephalography while treating patients both in-person and via telemedicine, proving ketamine's effectiveness in neurocritical care settings regardless of delivery method.
Abstract
There is not a preferred medication for treating refractory status epilepticus (RSE) and intravenous ketamine is increasingly used. Ketamine effica...
MDMA-assisted psychotherapy for PTSD in adolescents: rationale, potential, risks, and considerations.
European child & adolescent psychiatry – November 01, 2024
Summary
No Summary
Abstract
3,4-Methylenedioxymetamphetamine(MDMA)-assisted psychotherapy (MDMA-AP) is a proposed treatment for posttraumatic stress disorder (PTSD) that may b...
Tags
Recent Interventions for Acute Suicidality Delivered in the Emergency Department: A Scoping Review.
The western journal of emergency medicine – November 01, 2024
Summary
Emergency departments now have promising new tools to help suicidal patients. Ketamine and Crisis Response Planning (CRP) show particular potential for rapid intervention. Single-dose ketamine treatment and brief psychological interventions delivered in the ER helped reduce acute suicidal thoughts. While sample sizes were small, both approaches proved quick to implement and showed meaningful results in stabilizing patients during critical moments.
Abstract
Suicidality is a growing problem in the US, and the emergency department (ED) is often the front line for the management and effective treatment of...
Protocol for Comparing Benzodiazepine-Ketamine and Benzodiazepine-Fentanyl Sedation in Phacoemulsification (BEKEF): A Double-Blind Crossover Non-Inferiority Clinical Trial Study.
Cureus – November 01, 2024
Summary
During cataract surgery, finding the right balance of sedation is crucial for patient comfort. Medical experts are evaluating whether ketamine could be a better partner to standard sedatives than fentanyl during phacoemulsification procedures. The study will track 48+ patients receiving both combinations across their two eyes, measuring sedation quality, surgical ease, and patient comfort. This research could revolutionize how doctors keep patients comfortable during these common but delicate procedures.
Abstract
Cataract surgery, particularly phacoemulsification, often requires sedation alongside topical anesthesia to manage patient anxiety and discomfort. ...
Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): commentary, Joks et al.
The British journal of psychiatry : the journal of mental science – November 01, 2024
Summary
Breakthrough findings show ketamine injections could offer new hope for people with severe depression who haven't responded to traditional treatments. Weekly subcutaneous doses significantly reduced depressive symptoms in patients with major depressive disorder, working faster than conventional medications. While esketamine nasal sprays are already approved, this injection method shows promise as an alternative delivery system.
Abstract
Regarding the article, 'Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KAD...
The role of NMDA-receptor type glutamatergic antagonists dextromethorphan or ketamine in the treatment of nonketotic hyperglycinemia: A critical reassessment.
Molecular genetics and metabolism – November 01, 2024
Summary
A surprising shift in understanding Nonketotic hyperglycinemia's pathophysiology is emerging. While excess glycine was once thought to overactivate brain receptors, leading to trials with Dextromethorphan or Ketamine, new insights reveal a crucial activator is actually *decreased*. This challenges the initial hypothesis, as clinical evidence hasn't shown these drugs provide added benefit. A critical reevaluation of Dextromethorphan and Ketamine's systematic use is vital for optimal patient care.
Abstract
The recognition of glycine as an endogenous ligand at the allosteric activation site of the NMDA-type glutamatergic receptor led to the assumption ...
Psychedelic and MDMA-Related Adverse Effects-A Call for Action.
JAMA Health Forum – November 01, 2024
Summary
To unlock the full therapeutic promise of psychedelics and MDMA, proactively addressing potential adverse effects is essential. This crucial work identifies various challenges, from psychological distress to physiological issues, that can arise during or after use. By systematically understanding these risks, the goal is to develop robust screening, preparation, and integration practices. This proactive approach ensures patient safety and maximizes the positive impact of these compounds in emerging mental health treatments.
Abstract
Psychedelic and MDMA-Related Adverse Effects-A Call for Action.
Intraoperative Pain Management for Treatment-Resistant Complex Regional Pain Syndrome: A Case Report.
Cureus – November 01, 2024
Summary
Innovative pain management breakthrough: Doctors successfully treated severe complex regional pain syndrome using targeted nerve surgery combined with intraoperative ketamine. This approach provided immediate relief for chronic neuropathic pain and reduced post-surgery opioid needs. The patient's dramatic improvement highlights how understanding CRPS pathophysiology leads to better outcomes, especially when treating advanced stages of CRPS.
Abstract
Complex regional pain syndrome (CRPS) is a chronic neuropathic pain disorder often following trauma, associated with severe pain and autonomic dist...
Myelin oligodendrocyte glycoprotein antibody-associated cerebral cortical encephalitis with super-refractory status epilepticus.
Brain & development – November 01, 2024
Summary
A rare form of autoimmune encephalitis linked to myelin oligodendrocyte glycoprotein can trigger severe, uncontrollable seizures. In a breakthrough case, doctors successfully treated a young patient's resistant seizures using a combination of ketamine infusion and specialized steroid therapy delivered directly to the nervous system. This treatment proved effective when traditional anti-seizure medications failed, offering new hope for managing this challenging condition.
Abstract
Seizures are commonly reported in patients with myelin oligodendrocyte glycoprotein antibody-associated cerebral cortical encephalitis (MOG-CCE). H...
Psilocybin for major depressive disorder: An updated systematic review and meta-analysis of randomized clinical trials
Journal of Psychopharmacology – October 31, 2024
Summary
Psilocybin, a classic hallucinogen, significantly reduces depression symptoms. A systematic review and meta-analysis of clinical trials, sourced from MEDLINE and Cochrane Library, revealed a large, clinically observable reduction (SMC: -1.24) in depressive symptomatology compared to placebo. This serotonergic medicine, a chemically synthesized alkaloid, shows promise in psychiatry and clinical psychology. Its influence on neurotransmitter receptors offers a novel approach for mental health, outperforming traditional treatments for depression.
Abstract
Background: Due to the unsatisfactory therapeutic effects of current antidepressants, research has been launched into alternative treatment approac...
Efficacy of esketamine for perinatal depression: a systematic review and meta-analysis.
CNS spectrums – October 31, 2024
Summary
Breakthrough findings show esketamine significantly reduces postpartum depression (PPD) risk. This nasal spray treatment, already proven effective for treatment-resistant depression, cut PPD rates by 70% when given during childbirth. The medication helps prevent major depressive disorder in new mothers, with benefits lasting up to 6 weeks after delivery, offering new hope for perinatal depression management.
Abstract
Postpartum depression (PPD), now referred to as perinatal depression, is a prevalent and debilitating mood disorder that reduces health-related qua...
Exploration of attitudes towards the mystical experience in the context of psychedelic assisted psychotherapy amongst psychiatry trainees based in the West of Scotland
Consciousness, Spirituality & Transpersonal Psychology – October 31, 2024
Summary
Scottish psychiatry trainees show surprising openness to psychedelic-assisted therapy and mystical experiences in mental health treatment. Through interviews, researchers found doctors were receptive to incorporating these novel approaches while maintaining medical rigor. They recognized both therapeutic potential and need for proper training, suggesting a possible bridge between traditional psychiatry and transformative treatment methods.
Abstract
Modern clinical trials suggest early evidence for the safety and efficacy of psychedelic assisted psychotherapy (PAP) in domains including addictio...
Acute Psychedelic Reactions, Post-Acute Changes in Dysfunctional Attitudes, and Psychedelic-Associated Changes in Wellbeing.
J Psychoactive Drugs – October 30, 2024
Summary
Remarkably, positive psychedelic experiences can profoundly shift negative thought patterns. Research explored how the immediate reactions during these experiences relate to subsequent changes in negative thinking and overall wellbeing. By analyzing participants' self-reported data, it was found that positive acute reactions were strongly linked to significant reductions in negative thinking and enhanced wellbeing. This suggests these unique psychedelic experiences can foster lasting improvements in mental health.
Abstract
Acute Psychedelic Reactions, Post-Acute Changes in Dysfunctional Attitudes, and Psychedelic-Associated Changes in Wellbeing.
Efficacy and safety of esketamine combined with propofol for conscious sedation in painless colonoscopy: a prospective, randomized, double-blind controlled clinical trial.
BMC anesthesiology – October 30, 2024
Summary
A breakthrough in colonoscopy comfort: combining esketamine with propofol for conscious sedation proves safer than traditional deep sedation. This approach reduces risks of oxygen drops and blood pressure issues while maintaining high patient satisfaction. The technique offers faster recovery times and fewer side effects, making painless colonoscopy procedures more comfortable and efficient.
Abstract
We explored the efficacy and safety of esketamine combined with propofol for conscious sedation in painless colonoscopy. A total of 195 patients wh...
A narrative exploration of psilocybin’s potential in mental health
Frontiers in Psychiatry – October 30, 2024
Summary
Psilocybin, a potent hallucinogen, is demonstrating high therapeutic potential in psychiatry. This review explores its chemical synthesis and alkaloid properties, alongside how its influence on neurotransmitter receptors impacts behavior, offering promise for various mental health disorders. Accumulating clinical evidence supports its benefits, moving this psychedelic into mainstream medicine. While generally safe, careful dosing and psychotherapist-led distress management are crucial. This burgeoning field of Psychedelics and Drug Studies aims to integrate psilocybin into psychology and psychiatric treatments, paving the way for its wider acceptance.
Abstract
Psilocybin, a psychoactive substance, has recently garnered attention for its high therapeutic potential in psychiatry. In this study, we investiga...
Differentiation of Ayahuasca Samples According to Preparation Mode and Botanical Varieties Using Metabolomics.
Journal of psychoactive drugs – October 29, 2024
Summary
Traditional ayahuasca brews, made from Banisteriopsis caapi vines and other plants, show remarkable variation in their chemical makeup based on preparation methods. Using advanced metabolomics and mass spectrometry, researchers analyzed 126 samples from different religious groups, finding distinct chemical profiles and antioxidant properties linked to specific preparation techniques.
Abstract
Ayahuasca is a brew traditionally prepared with a mixture of Psychotria viridis leaves and Banisteriopsis caapi vine and has demonstrated therapeut...
Into the wild frontier: Mapping the terrain of adverse events in psychedelic-assisted therapies.
J Psychopharmacol – October 29, 2024
Summary
As psychedelic therapy gains momentum in mental health treatment, understanding its risks is crucial. This comprehensive analysis examines adverse events during psychedelic-assisted therapy, from mild anxiety to rare psychological challenges. While most sessions prove safe under proper supervision, the review identifies key factors for minimizing risks: careful patient screening, therapist training, and structured support systems during sessions.
Abstract
Into the wild frontier: Mapping the terrain of adverse events in psychedelic-assisted therapies.
“The mushroom was more alive and vibrant”: Patient reports of synthetic versus organic forms of psilocybin
Journal of Psychedelic Studies – October 29, 2024
Summary
For mental health, whole Psilocybe mushrooms and their extracts offer a more natural and superior experience than synthetic psilocybin. Participants in a Psilocybin-Assisted Therapy program for end-of-life distress reported that while synthetic psilocybin, whole *Psilocybe cubensis*, and mycological extract all provided emotional insight and mystical experiences, synthetic psilocybin felt less natural and had an inferior overall quality. This suggests future Psychedelics and Drug Studies in psychology and psychiatry should prioritize natural mushroom compounds in medicine, moving beyond synthetic drug forms.
Abstract
Abstract Interest in psychedelic research in the West is surging, however, clinical trials have almost exclusively studied synthetic compounds such...
Yangonin, one of the kavalactones isolated from Piper methysticum G. Forst, acts through cannabinoid 1 (CB1) receptors to induce an intrathecal anti-hyperalgesia.
Journal of ethnopharmacology – October 28, 2024
Summary
No Summary
Abstract
Piper methysticum G. Forst (Piperaceae) is traditionally consumed in Polynesian culture. The roots are used to produce an entheogenic drink and tra...
Psilocin, the Psychoactive Metabolite of Psilocybin, Modulates Select Neuroimmune Functions of Microglial Cells in a 5-HT2 Receptor-Dependent Manner
Molecules – October 28, 2024
Summary
A compelling finding: Psilocybin's active metabolite, psilocin, a hallucinogen, shows significant potential in modulating brain inflammation. In pharmacology and neuroscience, experiments on microglia-like cells revealed this chemistry, acting on specific receptors, inhibited their phagocytic activity and reduced reactive oxygen species and nitric oxide production. This neurotransmitter receptor influence on behavior is crucial. These drug studies, involving psychedelics and chemical synthesis of alkaloids, suggest psilocin could treat neurodegenerative conditions, offering new avenues in psychology and medicine.
Abstract
Neuroinflammation that is caused by microglia, the main immune cells of the brain, contributes to neurodegenerative diseases. Psychedelics, includi...
Preclinical models for evaluating psychedelics in the treatment of major depressive disorder.
British journal of pharmacology – October 28, 2024
Summary
No Summary
Abstract
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid-acting antidepressants (...
Ketamine-induced altered states of consciousness: a systematic review of implications for therapeutic outcomes in psychiatric practices.
European archives of psychiatry and clinical neuroscience – October 28, 2024
Summary
Ketamine's ability to induce altered states of consciousness may be key to its remarkable antidepressant effects. Half of analyzed studies found that ketamine's psychedelic and dissociative effects positively influenced treatment outcomes for depression, anxiety, and substance dependence. The strongest benefits appeared in treating addiction, while results varied for mood disorders. IV administration showed more promise than other methods.
Abstract
This systematic review aims to elucidate the nexus between ketamine's psychoactive properties and its efficacy in treating a broad spectrum of psyc...
Ketamine and chronic treatment-resistant depression: real-world practice and after relapse.
BMC psychiatry – October 28, 2024
Summary
Ketamine shows promise as a rapid-acting treatment for chronic treatment-resistant depression (TRD), but its effects require careful management. In real-world clinical practice, patients receiving six ketamine infusions showed significant improvement, with 67% responding positively to treatment. While the antidepressant effect was notable, symptoms typically returned after relapse. MADRS scores helped track patient progress, suggesting ketamine may work best as an adjuvant therapy alongside other treatments.
Abstract
Chronic treatment-resistant depression (TRD) poses a major challenge for clinicians. Ketamine has shown a rapid but short-lived antidepressant effe...
Advancing ketamine in the treatment hierarchy for refractory depression.
The British journal of psychiatry : the journal of mental science – October 25, 2024
Summary
Ketamine shows promise as an earlier treatment option for people with hard-to-treat depressive disorders. Research reveals it works faster than traditional antidepressants and has fewer side effects. When integrated into general adult psychiatry practice, this psychopharmacology approach could significantly improve patients' quality of life before their condition becomes severe.
Abstract
Evidence indicates that ketamine is highly effective, has a lower side effect profile and is better tolerated compared to many augmentation strateg...
Substrate recognition by the 4‐hydroxytryptamine kinase PsiK in psilocybin biosynthesis
FEBS Letters – October 24, 2024
Summary
Psilocybin, a natural hallucinogen, shows immense promise in Psychedelics and Drug Studies for mental health. Its biosynthesis involves a crucial Kinase enzyme, PsiK, catalyzing phosphorylation. Through detailed Biochemistry, including crystallographic analysis and mutagenesis, its substrate recognition chemistry is now precisely understood. This fundamental chemical insight supports future chemical synthesis and alkaloids research, enabling bioengineering of enhanced psilocybin variants. Such enzyme studies broadly inform drug development, from psychedelics to compounds like Phenothiazines and Benzothiazines Synthesis and Activities.
Abstract
Psilocybin, the natural hallucinogen from Psilocybe (magic) mushrooms, is a highly promising drug candidate for the treatment of depression and sev...
Critical appraisal of evidence supporting prescription of psychedelics from clinic websites in Ontario, Canada
PLoS ONE – October 24, 2024
Summary
Psychedelic clinics in Ontario are promoting psilocybin and other psychedelics for an astonishing 47 distinct medical conditions, often with insufficient scientific backing. An analysis of 10 clinic websites revealed only 2 out of 10 described potential risks. While 29 studies were cited for these medical prescriptions, most offered low-to-moderate "level 4" evidence, like case-series. This raises concerns for mental health patients seeking medicine, underscoring the need for transparent, high-quality information regarding psychedelic treatments in family medicine and psychiatry.
Abstract
Psychedelics, including ketamine, 3,4-Methyl enedioxy methamphetamine (MDMA), and psilocybin, have gained attention for their potential therapeutic...
Expert recommendations for Germany’s integration of psychedelic-assisted therapy
BMC Medical Education – October 24, 2024
Summary
Australia has already approved MDMA and psilocybin for mental health, highlighting Europe's urgent need to advance medical education in psychedelic-assisted therapy. With USA trials in Phase III, Germany is poised to lead Europe in developing robust frameworks for integrating innovative Psychedelics and Drug Studies into Medicine. This includes defining ethical Psychotherapy Techniques and Applications, practitioner training, and regulatory oversight. Such infrastructure development aims to ensure proficient care, potentially reclaiming Europe's historical lead in Psychology and psychiatric innovation, as seen with Switzerland's 2014 reintroduction of MDMA and LSD for restricted medical use.
Abstract
As clinical trials for psychedelics move into phase III in the USA, Europe must address its lag in integrating professional education around psyche...
Psilocybin Reduces Grooming in the SAPAP3 Knockout Mouse Model of Compulsive Behaviour
OpenAlex – October 24, 2024
Summary
A single 1 mg/kg dose of Psilocybin dramatically reduced obsessive compulsive-like behaviors for up to a week in male knockout mice, a key model in Psychology for compulsive disorders. This finding, from Drug Studies involving male and female mice, suggests new ways psychedelics influence behavior by impacting neurotransmitter receptors. It also reduced grooming in female mice. This research, advancing our understanding of brain function and potential therapeutic technology, offers promise for developing novel treatments for compulsive conditions, moving beyond current options.
Abstract
Abstract Psilocybin is a serotonergic psychedelic compound which shows promise for treating compulsive behaviours. This is particularly pertinent a...
Effect of different doses of esketamine on the median effective concentration of propofol for inhibiting body movement during hysteroscopy.
Scientific reports – October 24, 2024
Summary
Combining anesthetics strategically can lead to better patient outcomes. When esketamine is paired with propofol during hysteroscopy procedures, doctors can use less propofol while still effectively preventing patient movement. Higher doses of esketamine (0.3 mg/kg) allowed for a 20% reduction in required propofol levels, while also reducing post-operative anxiety and depression scores.
Abstract
The objective of this study is to investigate the effects of various doses of esketamine on the median effective concentration (EC50) of propofol r...
How Bud Craig's Insights Reshape the Research on Pain and Mind-Body Therapies.
Current topics in behavioral neurosciences – October 23, 2024
Summary
No Summary
Abstract
With his elegant studies, Bud Craig determined the structural neural basis for interoception and critically expanded our conceptual understanding o...
Ayahuasca drinking using a two-bottle choice procedure in male mice.
Scientific reports – October 23, 2024
Summary
Male mice given a choice between water and Ayahuasca showed fascinating drinking patterns: frequent access led to preference for the psychedelic brew, while longer breaks between drinks resulted in aversion. Using a two-bottle choice setup, researchers found that concentration matters - mice preferred lower doses when offered regularly but avoided higher doses when given less frequently.
Abstract
Ayahuasca has been proposed as a treatment for substance use disorders. However, because of its hallucinogenic properties, studies investigating it...
Rapid Effects of MDMA Administration on Self-Reported Personality Traits and Affect State: A Randomized, Placebo-Controlled Trial in Healthy Adults.
Journal of psychoactive drugs – October 23, 2024
Summary
In a groundbreaking clinical trial, MDMA showed promising effects on personality traits and emotional well-being. Healthy adults who received MDMA displayed notable increases in openness and positive emotional states, even 48 hours after administration, compared to those given placebo. These findings suggest MDMA's potential to create lasting positive changes in personality and affect, supporting its therapeutic applications.
Abstract
3,4-methylenedioxymethamphetamine (MDMA) assisted therapy has been shown to be a safe and effective treatment for PTSD and emerging research sugges...
Improvement in pain by using lidocaine combined with esketamine in elderly patients receiving local anaesthesia for percutaneous kyphoplasty: a randomized controlled study.
BMC anesthesiology – October 23, 2024
Summary
Adding esketamine to local anaesthesia dramatically improves pain control in older patients undergoing spine procedures. When combined with lidocaine during percutaneous kyphoplasty, this adjuvant medication achieved 100% patient satisfaction compared to just 48% with standard treatment. The combination proved especially effective for elderly patients, providing better pain relief and more stable vital signs throughout the procedure, all without significant side effects.
Abstract
Elderly patients often experience severe pain during percutaneous kyphoplasty under local anaesthesia. The aim of this work was to evaluate the eff...